There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Legend Biotech (LEGN – Research Report) and PolyPid (PYPD – Research Report) with bullish sentiments.
Legend Biotech (LEGN)
BMO Capital analyst Kostas Biliouris maintained a Buy rating on Legend Biotech today and set a price target of $79.00. The company’s shares closed last Monday at $52.18.
According to TipRanks.com, Biliouris is a 2-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Legend Biotech with a $69.67 average price target, which is a 30.1% upside from current levels. In a report issued on December 6, UBS also initiated coverage with a Buy rating on the stock with a $66.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
JMP Securities analyst Roy Buchanan reiterated a Buy rating on PolyPid today and set a price target of $3.00. The company’s shares closed last Monday at $0.73, close to its 52-week low of $0.65.
According to TipRanks.com, Buchanan ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
PolyPid has an analyst consensus of Moderate Buy, with a price target consensus of $3.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LEGN: